ICTA involved in the fight against microbial resistance via the S.O.L.V.E – AMR hub
You are an R&D player involved in the fight against microbial resistance (AMR)? And you are developing an anti-infectives programme?
Today, 10 October 2023, we celebrate the launch of :
S.O.L.V.E – AMR
(Solutions for Overcoming and Leveraging Versatile Efforts Against Microbial Resistance)
4 acknowledged providers in clinical research,
BIOASTER, CYNBIOSE, ICTA and PHARMALEX
combine their expertise and skills to deliver an integrated and innovative approach to support you throughout the development cycle of your antimicrobial agents.
From discovery to registration, through to pre-clinical and clinical development, S.OL.V.E. – AMR offers tailored solutions and innovative technologies to fast-track your anti-infectives from R&D to market
For more information, read the related press release